Genevant scores with Takeda again as LNPs continue to attract interest for RNA therapy
Barely five months after signing on to a $600 million deal with Takeda, Genevant has returned to ink another big biobuck tie-up with its new collaborators.
The Canadian and Swiss biotech, spawned out of Vivek Ramaswamy’s sprawling vant portfolio, has teamed up with Takeda for a licensing deal totaling $303 million, the companies announced Monday morning. Their focus will remain on the liver, with the new funds fueling work on nonviral gene therapies for 2 undisclosed rare liver diseases.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,300+ biopharma pros reading Endpoints daily — and it's free.